A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer-Reference-Cited by-同舟云学术

A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer

Published:2023-04 Issue:2 Volume:21 Page:265-272
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Makrakis Dimitrios^ORCID,Wright Jonathan L.,Roudier Martine P.,Garcia Jose,Vakar-Lopez Funda,Porter Michael P.,Wang Yan,Dash Atreya,Lin Daniel,Schade George^ORCID,Winters Brian,Zhang Xiotun,Nelson Peter,Mostaghel Elahe,Cheng Heather H.,Schweizer Michael,Holt Sarah K.^ORCID,Gore John L.,Yu Evan Y.,Lam Hung Ming^ORCID,Montgomery Bruce^ORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference40 articles.

1. Epidemiology of bladder cancer;Saginala;Med Sci Basel Switz,2020

2. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature;Mari;World J Urol,2018

3. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis;Yin;Oncologist,2016

4. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration;Vale;Eur Urol,2005

5. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman;New Engl J Med,2003

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues;Frontiers in Immunology;2024-02-19

2. Lifespan extension with mTOR inhibitors rapamycin, everolimus, and temsirolimus in Caenorhabditis elegans (Maupas, 1899);RUSS J NEMATOL;2024

3. Advances in the regulatory mechanisms of mTOR in necroptosis;Frontiers in Immunology;2023-12-18

4. Regulation of Eukaryotic Translation Initiation Factor 4E as a Potential Anticancer Strategy;Journal of Medicinal Chemistry;2023-09-19